Novel Vδ2-T Cells Derived Exosomes Treatment for Epstein-Barr Virus (EBV) Associated Cancers
- Therapeutic Biologics
- Reference No.
Key Problem and Market Opportunity
The global cancer therapeutics market is expected to grow from $128.1 billion in 2018 to $182.0 billion by 2023 at a CAGR of 7.3%. EBV associated cancer accounts for 1-2% of all cancers.
Current treatment options for EBV-associated tumors are very limited with remarkable unwanted off-target toxicities
The exosomes demonstrate an EBV-associated tumor specific tropism, ability to distinguish normal and infected B cells and capacity to trigger both tumor cell apoptosis and stimulate anti-tumor T cell activities.
Figure 1. Graph showing % apoptosis in autologous normal B cells and EBV-LCL after exosome treatment.
Stage of Development
Verified in EBV-associated B-cell lymphoma model
Key Advantages of the Technology
- Potential to be the first exosome therapy for the treatment of EBV-associated cancer
- Superiority over both conventional treatments, novel cell based treatments and other immune cell derived exosomes
Potential Product and Services
Novel therapeutic for the treatment of EBV associated cancers
- US provisional patent application No. 62916430
- Patent application submitted